Evidence map›Paper›PMID 34076787›Full record

ReviewClinical & experimental metastasis2021

Cancer cell metabolic plasticity in migration and metastasis.

Jenna A Mosier, Samantha C Schwager, David A Boyajian, Cynthia A Reinhart-King

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & experimental metastasis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 98 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jenna A Mosier *Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.
Samantha C Schwager *Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.
David A BoyajianDepartment of Radiology, Weill Cornell Medical College, New York, NY, USA.
Cynthia A Reinhart-KingDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA. cynthia.reinhart-king@vanderbilt.edu.ORCID http://orcid.org/0000-0001-6959-3914
Vanderbilt University · USCornell University · US

Funding

Molecular Determinants of Confined MigrationR01GM131178 · NIGMS · VANDERBILT UNIVERSITY · PI MARKOV, DMITRY · 2019 to 2022
$1.5M
National Science Foundation 1937963NIGMS NIH HHS GM131178
6 · The paper itself

Abstract

Metabolic reprogramming is a hallmark of cancer metastasis in which cancer cells manipulate their metabolic profile to meet the dynamic energetic requirements of the tumor microenvironment. Though cancer cell proliferation and migration through the extracellular matrix are key steps of cancer progression, they are not necessarily fueled by the same metabolites and energy production pathways. The two main metabolic pathways cancer cells use to derive energy from glucose, glycolysis and oxidative phosphorylation, are preferentially and plastically utilized by cancer cells depending on both their intrinsic metabolic properties and their surrounding environment. Mechanical factors in the microenvironment, such as collagen density, pore size, and alignment, and biochemical factors, such as oxygen and glucose availability, have been shown to influence both cell migration and glucose metabolism. As cancer cells have been identified as preferentially utilizing glycolysis or oxidative phosphorylation based on heterogeneous intrinsic or extrinsic factors, the relationship between cancer cell metabolism and metastatic potential is of recent interest. Here, we review current in vitro and in vivo findings in the context of cancer cell metabolism during migration and metastasis and extrapolate potential clinical applications of this work that could aid in diagnosing and tracking cancer progression in vivo by monitoring metabolism. We also review current progress in the development of a variety of metabolically targeted anti-metastatic drugs, both in clinical trials and approved for distribution, and highlight potential routes for incorporating our recent understanding of metabolic plasticity into therapeutic directions. By further understanding cancer cell energy production pathways and metabolic plasticity, more effective and successful clinical imaging and therapeutics can be developed to diagnose, target, and inhibit metastasis.

Indexed as

Cell MovementNeoplasm MetastasisEnergy MetabolismHumansNeoplasmsOxidative PhosphorylationATPCollective migrationExtracellular matrixGlycolysisOxidative phosphorylation

Identifiers

PMID34076787
OpenAlexW3165500636

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.